Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction: Hospitalized patients with acute decompensation (AD) of cirrhosis are at risk of progressing to acute-on-chronic liver failure (ACLF), significantly increasing their mortality. This study aimed to identify key predictors and patient trajectories predisposing to ACLF. Methods: In this multi-center, prospective study spanning two years, clinical, biochemical, and 90-day survival data were collected from 625 AD patients (EASL criteria) across North, South, and East India. We divided the cohort into a Derivation-cohort (DC: 318 patients) and a Validation-cohort (VC: 307 patients). Predictive models for pre-ACLF were derived, validated, and compared with established scores like MELD3.0 and CLIF-C AD. Results: Of 625 patients, (mean age 49, 83% male, 77.5% with alcohol-related liver disease), 32.2% progressed to ACLF. Patients progressing to ACLF showed significantly higher bilirubin (10.9vs.8.1mg/dl), leukocyte counts (9400vs.8000 per mm3), INR (1.9 vs.1.8), and MELD3.0 (28vs.25), but lower sodium (131vs.134mEq/L) and survival (62% vs.86%) compared to those without progression (p<0.05) in the DC. Consistent results were noted with AH, infection and HE as additional risk factors in VC. Liver failure at presentation [OR: 2.4 (in DC), 6.9 (in VC)] and the seven-day trajectories of bilirubin, INR, and MELD3.0 significantly predicted ACLF progression (p<0.001). A new PRE-ACLF Model showed superior predictive capability (AUC of 0.71 in DC and 0.82 in VC) compared to MELD3.0 and CLIF-C AD scores (p<0.05). Discussion: Approximately one-third of AD patients in this Indian cohort rapidly progressed to ACLF, resulting in high mortality. Early identification of patients at risk can guide targeted interventions to prevent ACLF.
Introduction: Hospitalized patients with acute decompensation (AD) of cirrhosis are at risk of progressing to acute-on-chronic liver failure (ACLF), significantly increasing their mortality. This study aimed to identify key predictors and patient trajectories predisposing to ACLF. Methods: In this multi-center, prospective study spanning two years, clinical, biochemical, and 90-day survival data were collected from 625 AD patients (EASL criteria) across North, South, and East India. We divided the cohort into a Derivation-cohort (DC: 318 patients) and a Validation-cohort (VC: 307 patients). Predictive models for pre-ACLF were derived, validated, and compared with established scores like MELD3.0 and CLIF-C AD. Results: Of 625 patients, (mean age 49, 83% male, 77.5% with alcohol-related liver disease), 32.2% progressed to ACLF. Patients progressing to ACLF showed significantly higher bilirubin (10.9vs.8.1mg/dl), leukocyte counts (9400vs.8000 per mm3), INR (1.9 vs.1.8), and MELD3.0 (28vs.25), but lower sodium (131vs.134mEq/L) and survival (62% vs.86%) compared to those without progression (p<0.05) in the DC. Consistent results were noted with AH, infection and HE as additional risk factors in VC. Liver failure at presentation [OR: 2.4 (in DC), 6.9 (in VC)] and the seven-day trajectories of bilirubin, INR, and MELD3.0 significantly predicted ACLF progression (p<0.001). A new PRE-ACLF Model showed superior predictive capability (AUC of 0.71 in DC and 0.82 in VC) compared to MELD3.0 and CLIF-C AD scores (p<0.05). Discussion: Approximately one-third of AD patients in this Indian cohort rapidly progressed to ACLF, resulting in high mortality. Early identification of patients at risk can guide targeted interventions to prevent ACLF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.